TECTONIC THERAPEUTIC, INC. Proceeds from Issuance of Private Placement
TECTONIC THERAPEUTIC, INC. (TECX) reported Proceeds from Issuance of Private Placement of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of private placement for the quarter ending 2026-06-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of private placement for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of private placement for the quarter ending 2025-12-31 was $0.00.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of private placement for the quarter ending 2025-09-30 was $0.00.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of private placement for fiscal 2025 was $173.10M.
- TECTONIC THERAPEUTIC, INC. proceeds from issuance of private placement for fiscal 2024 was $0.00.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | -$4.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$4.17M derived: sum of 3 quarters · filed 2026-08-06 | $173.10M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.17M derived: sum of 2 quarters · filed 2026-08-06 | $173.10M 10-Q · filed 2025-11-06 | $173.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$4.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $173.10M 10-Q · filed 2026-08-06 | $173.10M derived: sum of 3 quarters · filed 2026-08-06 | $173.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $177.27M 10-Q · filed 2026-05-07 | $177.27M derived: sum of 2 quarters · filed 2026-05-07 | $177.27M derived: sum of 3 quarters · filed 2026-05-07 | $177.27M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |